Prolymphocytic leukemia
diseaseOn this page
Also known as prolymphocytic leukaemia (B or T)prolymphocytic leukaemia (B or T-cell)prolymphocytic leukemia (B or T)prolymphocytic leukemia (B or T-cell)
Summary
Prolymphocytic leukemia (MONDO:0001023) is a cancer and 63 clinical trials. Top therapeutic interventions include fludarabine phosphate, foscarnet, and ibrutinib. A subtype of chronic leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 63
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | prolymphocytic leukemia |
| Mondo ID | MONDO:0001023 |
| MeSH | D015463 |
| DOID | DOID:1039 |
| NCIT | C3181 |
| SNOMED CT | 110006004 |
| UMLS | C0023486 |
| MedGen | 6062 |
| GARD | 0011965 |
| Is cancer (heuristic) | yes |
Also known as: prolymphocytic leukaemia (B or T) · prolymphocytic leukaemia (B or T-cell) · prolymphocytic leukemia · prolymphocytic leukemia (B or T) · prolymphocytic leukemia (B or T-cell)
Disease family
This is a subtype of chronic leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › chronic leukemia › prolymphocytic leukemia
Related subtypes (7): chronic monocytic leukemia, B-cell chronic lymphocytic leukemia, chronic eosinophilic leukemia, chronic neutrophilic leukemia, T-cell large granular lymphocyte leukemia, aggressive NK-cell leukemia, chronic myelomonocytic leukemia
Subtypes (3): splenic manifestation of prolymphocytic leukemia, B-cell prolymphocytic leukemia, T-cell prolymphocytic leukemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alemtuzumab, Alvocidib, Fludarabine Phosphate, Ibrutinib, Lenalidomide, Rituximab, Tafasitamab.
Clinical trials & evidence
Clinical trials
Clinical trials: 63.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 28 |
| PHASE1 | 18 |
| Not specified | 9 |
| PHASE1/PHASE2 | 7 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01231412 | PHASE3 | COMPLETED | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant |
| NCT01589302 | PHASE2 | ACTIVE_NOT_RECRUITING | PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia |
| NCT02007044 | PHASE2 | ACTIVE_NOT_RECRUITING | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia |
| NCT02029443 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter’s Syndrome or Prolymphocytic Leukemia |
| NCT03314974 | PHASE2 | RECRUITING | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders |
| NCT04195633 | PHASE2 | RECRUITING | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies |
| NCT05805605 | PHASE2 | RECRUITING | Allo HSCT Using RIC and PTCy for Hematological Diseases |
| NCT00005803 | PHASE1/PHASE2 | COMPLETED | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma |
| NCT00060424 | PHASE2 | COMPLETED | Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia |
| NCT00089011 | PHASE2 | COMPLETED | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
| NCT00098371 | PHASE2 | TERMINATED | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia |
| NCT00104858 | PHASE2 | COMPLETED | Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT00278213 | PHASE2 | COMPLETED | Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia |
| NCT00281931 | PHASE2 | TERMINATED | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia |
| NCT00309842 | PHASE2 | COMPLETED | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases |
| NCT00387426 | PHASE2 | TERMINATED | Sunitinib in Treating Patients With Idiopathic Myelofibrosis |
| NCT00719888 | PHASE2 | COMPLETED | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease |
| NCT01093586 | PHASE2 | COMPLETED | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| NCT01251575 | PHASE2 | COMPLETED | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant |
| NCT01419795 | PHASE2 | TERMINATED | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant |
| NCT01515176 | PHASE1/PHASE2 | COMPLETED | Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia |
| NCT01527045 | PHASE2 | COMPLETED | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies |
| NCT01629511 | PHASE1/PHASE2 | TERMINATED | Allogeneic Stem Cell Transplant for CLL |
| NCT01735604 | PHASE1/PHASE2 | UNKNOWN | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy |
| NCT02005289 | PHASE2 | COMPLETED | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL |
| NCT02285244 | PHASE2 | WITHDRAWN | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter’s Transformation |
| NCT02530515 | PHASE2 | COMPLETED | Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia |
| NCT02556931 | PHASE2 | COMPLETED | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies |
| NCT02661035 | PHASE2 | COMPLETED | Allo HSCT Using RIC for Hematological Diseases |
| NCT02662296 | PHASE2 | WITHDRAWN | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant |
| NCT02722668 | PHASE2 | COMPLETED | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep |
| NCT02991898 | PHASE2 | TERMINATED | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies |
| NCT03097770 | PHASE1/PHASE2 | COMPLETED | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 |
| NCT03185494 | PHASE1/PHASE2 | UNKNOWN | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 |
| NCT03246906 | PHASE2 | TERMINATED | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation |
| NCT04191187 | PHASE2 | COMPLETED | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies |
| NCT00025415 | PHASE1 | COMPLETED | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
| NCT00098488 | PHASE1 | TERMINATED | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia |
| NCT00343798 | PHASE1 | COMPLETED | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies |
| NCT00612612 | PHASE1 | TERMINATED | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUDARABINE PHOSPHATE | 4 | 21 |
| FOSCARNET | 4 | 4 |
| IBRUTINIB | 4 | 2 |
| ACALABRUTINIB | 4 | 1 |
| ALEMTUZUMAB | 4 | 1 |
| ATORVASTATIN CALCIUM | 4 | 1 |
| CARMUSTINE | 4 | 1 |
| CEFEPIME HYDROCHLORIDE | 4 | 1 |
| CLOFARABINE | 4 | 1 |
| GANCICLOVIR | 4 | 1 |
| IDELALISIB | 4 | 1 |
| IMATINIB MESYLATE | 4 | 1 |
| MITOXANTRONE HYDROCHLORIDE | 4 | 1 |
| MYCOPHENOLATE SODIUM | 4 | 1 |
| OFATUMUMAB | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| TAFASITAMAB | 4 | 1 |
| THIOTEPA | 4 | 1 |
| TISAGENLECLEUCEL | 4 | 1 |
| TREOSULFAN | 4 | 1 |
| VALGANCICLOVIR | 4 | 1 |
| ALVOCIDIB | 3 | 5 |
| DINACICLIB | 3 | 1 |
| OBATOCLAX MESYLATE | 3 | 1 |
| TANESPIMYCIN | 3 | 1 |
| AR-42 | 2 | 1 |
| SOTRASTAURIN ACETATE | 2 | 1 |
| ALVESPIMYCIN HYDROCHLORIDE | 1 | 1 |
| CHEMBL3647964 | 0 | 2 |
| CHEMBL4466205 | 0 | 2 |
Related Atlas pages
- Drugs: Fludarabine Phosphate, Foscarnet, Ibrutinib, Acalabrutinib, Alemtuzumab, Atorvastatin, Carmustine, Cefepime, Clofarabine, Ganciclovir, Idelalisib, Imatinib, Mitoxantrone, Mycophenolate, Ofatumumab, Sunitinib Malate, Tafasitamab, Thiotepa, Tisagenlecleucel, Treosulfan, Valganciclovir, Alvocidib, Dinaciclib, Obatoclax, Tanespimycin